Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
DMTF1 encodes a transcription factor that contains a cyclin D-binding domain, three central Myb-like repeats, and two flanking acidic transactivation domains at the N- and C-termini. Additionally we are shipping Cyclin D Binding Myb-Like Transcription Factor 1 Kits (11) and Cyclin D Binding Myb-Like Transcription Factor 1 Proteins (9) and many more products for this protein.
Showing 10 out of 165 products:
Human Polyclonal DMTF1 Primary Antibody for WB - ABIN2160618
Shin, Yang, Lee, Baek: Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. in Cellular signalling 2013
Human Polyclonal DMTF1 Primary Antibody for ELISA, WB - ABIN4305467
Inoue, Sugiyama, Taneja, Morgan, Frazier: Emerging roles of DMP1 in lung cancer. in Cancer research 2008
Chicken Polyclonal DMTF1 Primary Antibody for WB - ABIN2781143
Tschan, Gullberg, Shan, Torbett, Fey, Tobler: The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias. in Leukemia 2008
Human Polyclonal DMTF1 Primary Antibody for WB - ABIN411468
Lin, Xu, Liu, Sun, Chen, Yuan, Chen: KLF4 Promotes the Odontoblastic Differentiation of Human Dental Pulp Cells. in Journal of endodontics 2011
Low DMTF1 expression is associated with in bladder cancer.
findings imply that DMP1alpha- and beta-ratios are tightly regulated in hematopoietic cells and DMP1beta antagonizes DMP1alpha transcriptional regulation of ARF (show CDKN2A Antibodies) resulting in the alteration of cellular control with a gain in proliferation
This study reveals a pivotal role of combined Dmp1 (show DMP1 Antibodies) loss and cyclin D1 (show CCND1 Antibodies) overexpression in breast cancer.
LOH for hDMP1 was associated with luminal A category and longer relapse-free survival
new mechanism of p53 (show TP53 Antibodies) activation mediated by direct physical interaction between Dmp1 (show DMP1 Antibodies) and p53 (show TP53 Antibodies).
hDMP1beta antagonizes hDMP1alpha activity and cellular functions of hDMP1 may be regulated by cellular hDMP1 isoform levels
Loss of heterozygosity (LOH) of the hDMP1 gene was detectable in approximately 35% of human lung carcinomas, which was found in mutually exclusive fashion with LOH of INK4a/ARF or that of P53. DMP1 is a pivotal tumor suppressor for human lung cancers.
WT1 (show WT1 Antibodies) downregulation during myeloid differentiation of NB4 and HL60 leukemic cell lines is associated with increased tumor repressor hDMP1 mRNA levels
Results implicate Dmtf1 in the regulation of HSC (show FUT1 Antibodies) function through novel cell cycle-regulatory mechanisms.
Data show that Dmp1 (show DMP1 Antibodies) directly bound to the genomic loci of Areg (show AREG Antibodies), Tsp-1 (show GZMA Antibodies), JunB (show JUNB Antibodies) and Egr1 (show EGR1 Antibodies).
a novel Jun (show JUN Antibodies)-Dmp1 (show DMP1 Antibodies) pathway directly links oncogenic Ras-Raf (show RAF1 Antibodies) signaling and p19(Arf (show CDKN2A Antibodies)), independent of the classical cyclin D1 (show CCND1 Antibodies)/Cdk4 (show CDK4 Antibodies)-Rb-E2F (show E2F1 Antibodies) pathway
The Dmp1 (show DMP1 Antibodies)-Arf (show CDKN2A Antibodies) pathway is repressed by p65 (show NFkBP65 Antibodies) in response to genotoxic stress.
Approximately 40% of K-ras(LA) lung tumors from Dmp1(+/+) mice lost one allele of the Dmp1 gene, suggesting the primary involvement of Dmp1 in K-ras-induced tumorigenesis.
This gene encodes a transcription factor that contains a cyclin D-binding domain, three central Myb-like repeats, and two flanking acidic transactivation domains at the N- and C-termini. The encoded protein is induced by the oncogenic Ras signaling pathway and functions as a tumor suppressor by activating the transcription of ARF and thus the ARF-p53 pathway to arrest cell growth or induce apoptosis. It also activates the transcription of aminopeptidase N and may play a role in hematopoietic cell differentiation. The transcriptional activity of this protein is regulated by binding of D-cyclins. This gene is hemizygously deleted in approximately 40% of human non-small-cell lung cancer and is a potential prognostic and gene-therapy target for non-small-cell lung cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
cyclin D binding myb-like transcription factor 1
, cyclin-D-binding Myb-like transcription factor 1-like
, cyclin-D-binding Myb-like transcription factor 1
, cyclin D-binding Myb-like protein
, cyclin-D-interacting Myb-like protein 1
, D-interacting myb-like protein
, cyclin D binding myb-like transcription factor 1D-interacting myb-like protein